Michael Mee

Managing Director

2023 - Current

Principal

2019

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices.

Co-Founder

2019

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells and gene therapies as medicines. This new class of medicines is based on recent scientific advances that make it possible to treat a broad array of diseases. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that will change how we approach treating disease.

Senior Associate

2017 - 2019

Fueled by curiosity and a quest for new sources of future value, Flagship conceives, creates, resources and grows first-in-category life sciences companies. Our unique, systematic, hypothesis-driven innovation process empowers us simultaneously to explore the world’s biggest problems and to conceive disruptive scientific solutions. Our ventures deliver breakthrough medicines, maximize the potential of new agricultural practices, and power the world with innovative resources. We call this Pioneering. Since our founding in 2000, we have originated and fostered the development of more than 75 scientific ventures resulting in $19 billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents. Innovation is our currency. Our creativity, optimism, boundless energy, and curiosity fuel Flagship’s success. We pioneer scientific ventures for life.

Associate

2015 - 2017

VentureLabs Fellow

2015 - 2015

Co-Founder and Head of Innovation

2016 - 2018

Cobalt Biomedicine is developing a new class of therapeutics based on the ability to deliver into cells essentially any biological payload, ranging from defined molecular polymers to cellular organelles, with unprecedented cell specificity. This approach enables direct and highly targeted intervention inside the cell opening up vast opportunities across diverse therapeutic areas, with the potential to transiently or permanently correct for defects at the root of diseases. Cobalt Biomedicine was founded by Flagship Pioneering.

Scientific Strategy and Operations

2016 - 2016

Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship Pioneering, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome's natural roles in promoting health.

CoFounder

2014 - 2015

Doctoral Student

2010 - 2015